Form 4: Kineta Director's Holdings Converted and Options Canceled Following TuHURA Merger

A Kineta, Inc. director's common stock holdings were converted into TuHURA Biosciences, Inc. shares and stock options were canceled as a result of the recently completed merger between Kineta and TuHURA.

Summary

• Kimberlee C Drapkin, a Director of Kineta, Inc., reported changes in her beneficial ownership of Kineta securities on June 30, 2025.
• All 13,794 shares of Kineta Common Stock directly owned by Ms. Drapkin were disposed of, resulting in 0 shares beneficially owned following the transaction.
• All 20,000 stock options to purchase Kineta Common Stock with an exercise price of $2.58 were also disposed of, resulting in 0 options beneficially owned.
• These transactions occurred pursuant to the Agreement and Plan of Merger, dated December 11, 2024, as amended on May 5, 2025, between TuHURA Biosciences, Inc. and Kineta, Inc.
• Under the merger agreement, Kineta merged into wholly-owned subsidiaries of TuHURA, with Merger Sub II surviving as a wholly-owned subsidiary of TuHURA.
• Each outstanding share of Kineta Common Stock was cancelled and converted into the right to receive 0.185298 shares of TuHURA Common Stock.
• Kineta Common Stock holders are also entitled to a pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses.
• Additionally, Kineta Common Stock holders have the right to a pro rata share of cash consideration from disposed legacy Kineta assets.
• Stock options to purchase Kineta Common Stock with an exercise price greater than $0.64 were canceled and extinguished for no consideration at the effective time of the First Merger.

Sentiment

Score: 5

Explanation: The document is a factual report of transactions resulting from a merger. While the cancellation of options for no consideration is negative for the option holder, the conversion of shares into the acquiring company's stock, with potential future share and cash considerations, presents a mixed outcome for former Kineta shareholders. The overall sentiment is neutral as it reports a consequence of a corporate action rather than a performance update.

Positives

• Kineta common stock holders, including the reporting person, received 0.185298 shares of TuHURA Common Stock for each Kineta share.
• Kineta common stock holders are entitled to a pro rata portion of an additional 1,129,884 shares of TuHURA Common Stock to be issued six months post-merger.
• Kineta common stock holders have the right to a pro rata share of cash consideration from disposed legacy Kineta assets.

Negatives

• All Kineta Common Stock held by the reporting person was cancelled.
• Stock options with an exercise price greater than $0.64, including the 20,000 options held by the reporting person with an exercise price of $2.58, were canceled and extinguished for no consideration.

Risks

• The issuance of 1,129,884 shares of TuHURA Common Stock six months following the closing of the Mergers is subject to adjustment for losses incurred or accrued during that six-month period.

Future Outlook

Kineta common stock holders are expected to receive a pro rata portion of 1,129,884 shares of TuHURA Common Stock six months following the closing of the Mergers, subject to adjustment for losses. They are also entitled to a pro rata share of cash consideration from disposed legacy Kineta assets.

Industry Context

This filing reflects the finalization of a merger and acquisition (M&A) event, a common strategic move in the biotechnology and pharmaceutical sectors. M&A activities often aim to consolidate assets, expand pipelines, or achieve synergies, leading to changes in corporate structure and shareholder holdings.

Stakeholder Impact

• Shareholders of Kineta, Inc. had their shares converted into TuHURA Biosciences, Inc. common stock and gained rights to future contingent share and cash distributions.
• Holders of Kineta stock options with exercise prices above $0.64 had their options canceled without consideration.

Next Steps

• Issuance of pro rata portion of 1,129,884 shares of TuHURA Common Stock to former Kineta stockholders six months following the closing of the Mergers.
• Distribution of pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.

Key Dates

Keywords

Kineta, TuHURA Biosciences, Merger, Form 4, Insider Transaction, Stock Option, Common Stock, Acquisition, Beneficial Ownership, Corporate Action